Title:Prominent Targets for Cancer Care: Immunotherapy Perspective
Volume: 19
Issue: 4
Author(s): Mehul Patel*, Aashka Thakkar, Priya Bhatt, Umang Shah, Ashish Patel, Nilay Solanki, Swayamprakash Patel, Sandip Patel, Karan Gandhi and Bhavesh Patel
Affiliation:
- Department of Pharmaceutical Chemistry and Analysis, Ramanbhai Patel College of Pharmacy, Charotar University of
Science and Technology, CHARUSAT Campus, Changa, Gujarat, 388421, India
Keywords:
Cancer immunotherapy, monoclonal antibodies, T Cell, anti-tumor responses, check point blockade, cancer treatment.
Abstract:
Objective: Recent scientific advances have expanded insight into the immune system and
its response to malignant cells. In the past few years, immunotherapy has attained a hallmark for
cancer treatment, especially for patients suffering from the advanced-stage disease. Modulating the
immune system by blocking various immune checkpoint receptor proteins through monoclonal antibodies
has improved cancer patients' survival rates.
Methods: The scope of this review spans from 1985 to the present day. Many journals, books, and
theses have been used to gather data, as well as Internet-based information such as Wiley, PubMed,
Google Scholar, ScienceDirect, EBSCO, SpringerLink, and Online electronic journals.
Key Findings: Current review elaborates on the potential inhibitory and stimulatory checkpoint
pathways which are emerged and have been tested in various preclinical models, clinical trials, and
practices. Twenty-odd such significant checkpoints are identified and discussed in the present work.
Conclusion: A large number of ongoing studies reveal that combination therapies that target more
than one signaling pathway may become effective in order to maximize efficacy and minimize toxicity.
Moreover, these immunotherapy targets can be a part of integrated therapeutic strategies in
addition to classical approaches. It may become a paradigm shift as a promising strategy for cancer
treatment.
